Early signs and risk factors for the increased incidence of Epstein- Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus

Etienne Marc Sokal, Henedina Antunes, Claire Beguin, Monique Bodeus, Pierre Wallemacq, Jean De Ville De Goyet, Raymond Reding, Magda Janssen, Jean Paul Buts, Jean Bernard Otte

Research output: Contribution to journalArticle

Abstract

Background. Posttransplant lymphoproliferative disease (PTLD) is a life- threatening condition the incidence of which in pediatric solid organ transplantation may be related to the immunosuppressive load. It has been suggested that tacrolimus, a new and potent immunosuppressor, causes an increased incidence of this syndrome. Methods. The incidence, early signs, and risk factors for lymphoproliferative disease were reviewed in a cohort of 89 pediatric liver transplant recipients treated with tacrolimus. Results. Eighteen patients (20%) developed a PTLD-16 concomitant to a primary Epstein- Barr virus (EBV) infection and 2 with previous immunity against EBV. Three additional patients had preliminary signs of PTLD concomitant to primary EBV infection, but did not develop individualized lymphoid masses. Six patients died (6.7% of all tacrolimus-treated patients). Mean tacrolimus blood level during the 3 months preceding EBV infection reached 11.8 ± 1.8 ng/ml in PTLD patients versus 9.4 ± 3.4 ng/ml in non-PTLD patients (0.05

Original languageEnglish
Pages (from-to)1438-1442
Number of pages5
JournalTransplantation
Volume64
Issue number10
Publication statusPublished - Nov 27 1997

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Fingerprint Dive into the research topics of 'Early signs and risk factors for the increased incidence of Epstein- Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus'. Together they form a unique fingerprint.

  • Cite this